Skip to main content
Premium Trial:

Request an Annual Quote

Lynx, Millennium to Use MPSS for Gene-Expression Research

NEW YORK, May 15 - Lynx Therapeutics will use its Massively Parallel Signature Sequencing technology to help Millennium Pharmaceuticals study gene expression in certain blood cell populations, the companies said today.


Terms of the agreement call for Lynx to apply the MPSS technology in two separate studies: First the MPSS platform will be used to identify cell-specific gene markers for an undisclosed blood cell type.

In the second study, Lynx will use the platform to evaluate gene-expression patterns from RNA in peripheral blood monocytes following treatments with certain undisclosed compounds.


Click here for more informatin.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.